Scott & White Hospital Starts Phase II Clinical Trial - Next Test For Agent That Targets Prostate Cancer Cells

Scott & White has begun recruiting patients with recurring prostate cancer to participate in a clinical trial that uses a PSA (prostate specific antigen) activated chemical injected into the prostate that attaches to prostate cancer cells and causes cell death. “This is an important and exciting step in this process,” said Dr. Scott Coffield, the principal investigator, a urologist and professor of surgery at Scott & White.

More: continued here

Filed under: Prostate on April 17th, 2008